P

Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403

Watchlist Manager
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
Watchlist
Price: 14.68 CNY 0.89% Market Closed
Market Cap: 14B CNY

Pacific Shuanglin Bio pharmacy Co Ltd
Net Issuance of Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Pacific Shuanglin Bio pharmacy Co Ltd
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
P
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
Net Issuance of Debt
¥273m
CAGR 3-Years
21%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Net Issuance of Debt
¥1B
CAGR 3-Years
16%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Net Issuance of Debt
-¥730.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Net Issuance of Debt
¥948.1m
CAGR 3-Years
14%
CAGR 5-Years
62%
CAGR 10-Years
N/A
3SBio Inc
HKEX:1530
Net Issuance of Debt
-¥2.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Net Issuance of Debt
-¥54.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pacific Shuanglin Bio pharmacy Co Ltd
Glance View

Market Cap
14B CNY
Industry
Biotechnology

In the intricate web of China's burgeoning pharmaceutical landscape, Pacific Shuanglin Bio-Pharmacy Co., Ltd. stands out as a dynamic entity making waves in the biopharmaceutical sector. Founded with a vision to innovate and provide advanced healthcare solutions, the company has anchored its operations in the research, development, manufacturing, and marketing of a diverse range of bio-products and pharmaceutical drugs. The core of their business revolves around biotechnology, leveraging cutting-edge techniques to develop treatments aimed at addressing critical and complex health issues. Their product portfolio is robust, comprising antibiotics, cardiovascular medications, and other critical therapeutic areas, which emphasizes their capacity to adapt and thrive in a competitive market. Central to Pacific Shuanglin's success is its steadfast commitment to research and innovation. By investing heavily in R&D, the company not only ensures a steady pipeline of new products but also enhances the efficacy and safety of existing ones. This strategic focus not only stimulates growth but also fortifies their competitive edge. Their revenue model predominantly hinges on the successful commercialization of these pharmaceutical innovations, reinforcing a cycle of continual improvement and reinvestment in new medical solutions. Through strategic partnerships and a well-established distribution network, Pacific Shuanglin effectively reaches its target markets, both domestically and internationally, ensuring that their advanced medical products make a tangible difference in the lives of patients.

Pacific Shuanglin Bio pharmacy Co Ltd Intrinsic Value
HIDDEN
Show

See Also

What is Pacific Shuanglin Bio pharmacy Co Ltd's Net Issuance of Debt?
Net Issuance of Debt
273m CNY

Based on the financial report for Sep 30, 2025, Pacific Shuanglin Bio pharmacy Co Ltd's Net Issuance of Debt amounts to 273m CNY.

What is Pacific Shuanglin Bio pharmacy Co Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 5Y
12%

Over the last year, the Net Issuance of Debt growth was 174%. The average annual Net Issuance of Debt growth rates for Pacific Shuanglin Bio pharmacy Co Ltd have been 21% over the past three years , 12% over the past five years .

Back to Top